Who is sponsoring NCT04604028?

NCT04604028 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT04604028?

Interventions in NCT04604028: Lenalidomide [Leavdo®].

Is NCT04604028 still recruiting?

NCT04604028 is currently status unknown. Last updated 27 October 2020.

Last reviewed 2020-10-27 · How we verify

NCT04604028: LCMALT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma

Status unknown Phase 2 Last updated 27 October 2020

What this trial tests

Phase 2 trial testing Lenalidomide [Leavdo®] in Antibiotics-unresponsive MALT Lymphoma in 21 participants. Status unknown.

Timeline

10 November 2020

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	10 November 2020
Primary completion	31 December 2022
Estimated completion	31 December 2023
Sites	1 location across Taiwan

Drugs / interventions tested

Lenalidomide [Leavdo®] — full drug profile →

Conditions studied

Antibiotics-unresponsive MALT Lymphoma — all drugs for Antibiotics-unresponsive MALT Lymphoma →
Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma — all drugs for Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma →
Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT) — all drugs for Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT) →

Sponsor

National Taiwan University Hospital

Who can join

18 and older, any sex, with Antibiotics-unresponsive MALT Lymphoma or Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Considering that lenalidomide and cyclophosphamide are found to have anti-tumor effects in MALT lymphoma, the investigators speculated that combined lenalidomide and low-dose cyclophosphamide can increase the overall response rate as well as dural time of tumor remission, and avoid alternative treatments, including radiotherapy or chemotherapy-related adverse effects in antibiotics-unresponsive, relapsed or refractory extranodal MALT lymphoma. Therefore, in this proposal, the investigators will design a prospective phase II study to evaluate the treatment efficacies of combination of oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide \[Leavdo®\] 15 mg daily, day 1 to day 21; cyclophosphamide \[Endoxan\] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days) in patients with antibiotics-unresponsive, relapsed or refractory extranodal MALT lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current Status of the Spectrum and Therapeutics of <i>Helicobacter pylori</i>-Negative Mucosa-Associated Lymphoid Tissue Lymphoma.
Kuo SH, Yeh KH, Lin CW, Liou JM, et al · · 2022 · cited 13× · PMID 35205754 · DOI 10.3390/cancers14041005
Two rare cases of bronchus-associated lymphoid tissue lymphoma successfully treated with rituximab-bendamustine.
Panitz N, Gerhardt K, Becker C, Schleife H, et al · · 2021 · cited 2× · PMID 34401153 · DOI 10.1002/ccr3.4557

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04604028 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 27 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04604028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing